Is nausea a common side effect of Multiple Myeloma treatment? How can it be managed?

Yes nausea is fairly common both from multiple myeloma itself and from its treatments, and it can usually be prevented or controlled with the right plan. Myeloma can raise blood calcium or affect kidneys, which can trigger nausea and vomiting. ^[1] Myeloma therapies such as proteasome inhibitors, immunomodulatory drugs, monoclonal antibodies, and supportive agents frequently list nausea among their most reported side effects. ^[2] [PM23]

---

Why nausea happens in myeloma

• Disease-related causes: Myeloma may cause high blood calcium (hypercalcemia), which often leads to nausea and vomiting. ^[1] It can also cause anemia or kidney problems that contribute to feeling sick. ^[3]
• Treatment-related causes: Many standard regimens (for example, bortezomib-based combinations) report gastrointestinal side effects including nausea and vomiting. ^[2] Bortezomib trials showed nausea in a large proportion of patients and overall GI disorders (nausea, diarrhea, constipation, vomiting, appetite loss) in about three-quarters of participants. ^[4] Nausea rates with bortezomib were higher in multiple myeloma than in mantle cell lymphoma. ^[5]

---

How common is nausea with key therapies

• Proteasome inhibitors (e.g., bortezomib): Nausea is a frequent adverse effect; integrated studies reported high rates of GI toxicity, including nausea. ^[4] In multiple myeloma specifically, nausea was commonly observed and more frequent than in some other cancers treated with the same drug. ^[5]
• Monoclonal antibodies (e.g., daratumumab): In combinations, nausea appears among the most frequently reported adverse reactions in some trials, alongside diarrhea and fatigue. [PM23]
• Newer combinations (e.g., selinexor with DVd): Nausea was the most frequent non‑hematologic adverse event in a recent phase II study. [PM22]
• Supportive bone agents (e.g., denosumab) and certain bispecifics (e.g., elranatamab): Patient sheets advise that nausea and vomiting can occur and offer practical management tips. ^{[6] [7]}

---

Evidence-based prevention and treatment

Preventing nausea is more effective than chasing it after it starts. Major guidelines recommend tailoring anti‑nausea medicines to the emetogenic (nausea‑causing) risk of the regimen. ^{[8] [9]} Multidrug prophylaxis is used for higher-risk treatments, and simpler regimens for lower-risk ones. ^{[9] [10]}

Core antiemetic options

• Serotonin (5‑HT3) blockers such as ondansetron or palonosetron are first-line for many chemotherapy regimens. ^{[9] [8]}
• NK1 receptor blockers (e.g., aprepitant) are added for moderate to high-risk regimens to boost protection. ^{[9] [8]}
• Dexamethasone helps both acute and delayed nausea and is often part of prevention bundles. ^{[9] [8]}
• Dopamine antagonists (e.g., prochlorperazine, metoclopramide) can be used as rescue or adjuncts if symptoms break through. ^[8]
• Olanzapine may be considered for difficult or delayed nausea when standard options are not enough. ^[9]

Guidelines and institutional protocols list specific drugs including many myeloma agents and map them to recommended antiemetic strategies by risk level. ^{[10] [11]}

---

Practical self-care strategies

Alongside medicines, simple daily habits can make a big difference:

• Take anti‑nausea meds exactly as prescribed, even if you feel okay; prevention works best. ^{[6] [7]}
• Hydrate well unless you’ve been told to limit fluids. ^{[6] [7]}
• Eat small, frequent, bland meals (toast, crackers, bananas, rice), and avoid greasy or spicy foods. ^{[6] [7]}
• Try gentle activity like short walks to settle the stomach. ^{[6] [7]}
• Use relaxation, deep breathing, or meditation to reduce queasiness and anxiety. ^[12]
• Consider complementary options (with your care team’s okay) such as acupuncture or aromatherapy, which some people find helpful. ^{[13] [12]}
• Follow trusted nutrition guides tailored for treatment-related nausea to keep calories and protein up. ^[14]

---

When to contact your care team

• Persistent vomiting, inability to keep fluids down, signs of dehydration, or confusion can signal high calcium, kidney issues, or uncontrolled side effects and should be addressed promptly. ^{[1] [3]}
• Breakthrough nausea despite prevention may need medication adjustments or a different antiemetic plan aligned with guideline-based risk categories. ^{[9] [8] [10]}

---

Summary table: causes and management

Scenario	Likely cause	First steps	Next-level measures
New nausea in untreated myeloma	Hypercalcemia, anemia, renal issues	Labs and hydration	Treat hypercalcemia; adjust myeloma therapy as needed [1] [3]
Nausea after bortezomib or combo therapy	Drug-related GI effects	Scheduled 5‑HT3 blocker + dexamethasone	Add NK1 blocker or olanzapine per regimen risk [4] [9] [8]
Ongoing mild queasiness	Dietary/behavioral triggers	Small bland meals, fluids, gentle exercise	Rescue antiemetic as needed [6] [7] [8]
Hard-to-control or delayed nausea	Higher emetogenic risk or individual sensitivity	Full prophylaxis bundle	Reassess regimen, consider guideline updates and adjuncts [9] [10] [11]

---

Bottom line

Nausea is common in multiple myeloma and many of its treatments, but it is highly manageable with guideline‑based antiemetics and practical self‑care. Early prevention, prompt adjustments, and attention to disease-related causes (like high calcium) help most people feel significantly better. ^{[1] [2] [9] [8]}